

REFERENCES

- [1] C. S. H. govDate last updated: June 17 and 2019, "What Are HIV and AIDS?," *HIV.gov*, 17-Jun-2019. [Online]. Available: <https://www.hiv.gov/hiv-basics/overview/about-hiv-and-aids/what-are-hiv-and-aids>. [Accessed: 05-Sep-2019].
- [2] P. M. Sharp and B. H. Hahn, "Origins of HIV and the AIDS Pandemic," *Cold Spring Harb. Perspect. Med.*, vol. 1, no. 1, pp. a006841–a006841, Sep. 2011, doi: 10.1101/cshperspect.a006841.
- [3] "GHO | By category | Number of deaths due to HIV/AIDS - Estimates by WHO region," *WHO*. [Online]. Available: <http://apps.who.int/gho/data/node.main.623?lang=en>. [Accessed: 09-Sep-2019].
- [4] Y. Wang, Z. Lv, and Y. Chu, "HIV protease inhibitors: a review of molecular selectivity and toxicity," *HIVAIDS - Res. Palliat. Care*, p. 95, Apr. 2015, doi: 10.2147/HIV.S79956.
- [5] A. Brik and C.-H. Wong, "HIV-1 protease: mechanism and drug discovery," *Org. Biomol. Chem.*, vol. 1, no. 1, pp. 5–14, Dec. 2003, doi: 10.1039/b208248a.
- [6] N. I. Hariastuti, H. A. Wibowo, K. Adam, N. Subangkit, N. L. Kipuw, and N. Roselinda, "Potensi Resistensi Virus HIV-1 terhadap Terapi Anti Retroviral (ART) pada Pasien Voluntary Counseling and Testing (VCT) di Beberapa Kota di Indonesia," *Media Penelit. Dan Pengemb. Kesehatan.*, vol. 26, no. 3, pp. 151–156, Jan. 2017, doi: 10.22435/mpk.v26i3.4610.151-156.
- [7] "8.2 Pengobatan Antiretroviral (Antiretroviral therapy = ART) | ICHRC." [Online]. Available: <http://www.ichrc.org/82-pengobatan-antiretroviral-antiretroviral-therapy-art>. [Accessed: 09-Sep-2019].
- [8] E. Estrada, "On the Topological Sub-Structural Molecular Design (TOSS-MODE) in QSPR/QSAR and Drug Design Research," *SAR QSAR Environ. Res.*, vol. 11, no. 1, pp. 55–73, Mar. 2000, doi: 10.1080/10629360008033229.
- [9] A. P. Asmara, "Studi Qsar Senyawa Turunan Triazolopiperazin Amida Sebagai Inhibitor Enzim Dipeptidil Peptidase-IV (DPP IV) Menggunakan Metode Semiempirik AM," p. 9, 2013.
- [10] N. Hernández, R. Kiralj, M. M. C. Ferreira, and I. Talavera, "Critical comparative analysis, validation and interpretation of SVM and PLS regression models in a QSAR study on HIV-1 protease inhibitors," *Chemom. Intell. Lab. Syst.*, vol. 98, no. 1, pp. 65–77, Aug. 2009, doi: 10.1016/j.chemolab.2009.04.012.
- [11] V. Ravichandran, V. K. Mourya, and R. K. Agrawal, "Prediction of HIV-1 protease inhibitory activity of 4-hydroxy-5,6-dihydropyran-2-ones: QSAR study," *J. Enzyme Inhib. Med. Chem.*, vol. 26, no. 2, pp. 288–294, Apr. 2011, doi: 10.3109/14756366.2010.496364.
- [12] N. Saranya and S. Selvaraj, "QSAR Studies on HIV-1 Protease Inhibitors Using Non-Linearly Transformed Descriptors," *Curr. Comput. Aided-Drug Des.*, vol. 8, no. 1, pp. 10–49, Mar. 2012, doi: 10.2174/157340912799218534.
- [13] M. H. Fatemi, A. Heidari, and S. Gharaghani, "QSAR prediction of HIV-1 protease inhibitory activities using docking derived molecular descriptors," *J. Theor. Biol.*, vol. 369, pp. 13–22, Mar. 2015, doi: 10.1016/j.jtbi.2015.01.008.
- [14] R. Darnag, B. Minaoui, and M. Fakir, "QSAR models for prediction study of HIV protease inhibitors using support vector machines, neural networks and multiple linear regression," *Arab. J. Chem.*, vol. 10, pp. S600–S608, Feb. 2017, doi: 10.1016/j.arabjc.2012.10.021.
- [15] V. Ravichandran, K. Venkateskumar, S. Shalini, and R. Harish, "Exploring the structure–activity relationship of oxazolidinones as HIV-1 protease inhibitors—QSAR and pharmacophore modelling studies," *Chemom. Intell. Lab. Syst.*, vol. 154, pp. 52–61, May 2016, doi: 10.1016/j.chemolab.2016.03.017.
- [16] R. K. Singh, V. K. Sahu, S. A. Khan, and P. P. Singh, "QSAR Study of Peptidic HIV-1 Protease Inhibitors," vol. 18, pp. 35–50, Jan. 2011.
- [17] I. Kurniawan, D. Tarwidi, and Jondri, "QSAR modeling of PTP1B inhibitor by using Genetic algorithm-Neural network methods," *J. Phys. Conf. Ser.*, vol. 1192, p. 012059, Mar. 2019, doi: 10.1088/1742-6596/1192/1/012059.
- [18] S. Nagpal, S. Arora, S. Dey, and Shreya, "Feature Selection using Gravitational Search Algorithm for Biomedical Data," *Procedia Comput. Sci.*, vol. 115, pp. 258–265, 2017, doi: 10.1016/j.procs.2017.09.133.
- [19] I. I. Baskin, V. A. Palyulin, and N. S. Zefirov, "Neural Networks in Building QSAR Models," in *Artificial Neural Networks*, vol. 458, D. J. Livingstone, Ed. Totowa, NJ: Humana Press, 2006, pp. 133–154.
- [20] R. Guha and P. C. Jurs, "Interpreting Computational Neural Network QSAR Models: A Measure of Descriptor Importance," *J. Chem. Inf. Model.*, vol. 45, no. 3, pp. 800–806, May 2005, doi: 10.1021/ci050022a.
- [21] A.-L. Milac, S. Avram, and A.-J. Petrescu, "Evaluation of a neural networks QSAR method based on ligand representation using substituent descriptors," *J. Mol. Graph. Model.*, vol. 25, no. 1, pp. 37–45, Sep. 2006, doi: 10.1016/j.jmglm.2005.09.014.

- [22] S. A. Amin, N. Adhikari, S. Bhargava, T. Jha, and S. Gayen, "Structural exploration of hydroxyethylamines as HIV-1 protease inhibitors: new features identified," *SAR QSAR Environ. Res.*, vol. 29, no. 5, pp. 385–408, May 2018, doi: 10.1080/1062936X.2018.1447511.
- [23] N. M. O'Boyle, M. Banck, C. A. James, C. Morley, T. Vandermeersch, and G. R. Hutchison, "Open Babel: An open chemical toolbox," *J. Cheminformatics*, vol. 3, no. 1, p. 33, Dec. 2011, doi: 10.1186/1758-2946-3-33.
- [24] H. Moriwaki, Y.-S. Tian, N. Kawashita, and T. Takagi, "Mordred: a molecular descriptor calculator," *J. Cheminformatics*, vol. 10, no. 1, p. 4, Dec. 2018, doi: 10.1186/s13321-018-0258-y.
- [25] C. W. Yap, "PaDEL-descriptor: An open source software to calculate molecular descriptors and fingerprints," *J. Comput. Chem.*, vol. 32, no. 7, pp. 1466–1474, May 2011, doi: 10.1002/jcc.21707.
- [26] "Enzyme inhibitors." [Online]. Available: <https://www.ucl.ac.uk/~ucbcdab/enzass/inhibition.htm>. [Accessed: 12-Jan-2020].
- [27] Q. Huang *et al.*, "Proteochemometric Modeling of the Bioactivity Spectra of HIV-1 Protease Inhibitors by Introducing Protein-Ligand Interaction Fingerprint," *PLoS ONE*, vol. 7, no. 7, p. e41698, Jul. 2012, doi: 10.1371/journal.pone.0041698.
- [28] J. P. Papa *et al.*, "Feature selection through gravitational search algorithm," in *2011 IEEE International Conference on Acoustics, Speech and Signal Processing (ICASSP)*, Prague, Czech Republic, 2011, pp. 2052–2055, doi: 10.1109/ICASSP.2011.5946916.
- [29] "Newton's law of gravitation," *Encyclopedia Britannica*. [Online]. Available: <https://www.britannica.com/science/Newtons-law-of-gravitation>. [Accessed: 08-Dec-2019].
- [30] E. Rashedi, H. Nezamabadi-pour, and S. Saryazdi, "GSA: A Gravitational Search Algorithm," *Inf. Sci.*, vol. 179, no. 13, pp. 2232–2248, Jun. 2009, doi: 10.1016/j.ins.2009.03.004.
- [31] E. Rashedi, H. Nezamabadi-pour, and S. Saryazdi, "BGSA: binary gravitational search algorithm," *Nat. Comput.*, vol. 9, no. 3, pp. 727–745, Sep. 2010, doi: 10.1007/s11047-009-9175-3.
- [32] S. S. Haykin, *Neural networks and learning machines*, 3rd ed. New York: Prentice Hall, 2009.
- [33] Suyanto, *Artificial Intelligence Searching, Reasoning, Planning, dan Learning*. Informatika Bandung, 2014.
- [34] "Dasar Pemahaman Neural Network." [Online]. Available: <https://socs.binus.ac.id/2012/07/26/konsep-neural-network/>. [Accessed: 01-Oct-2019].
- [35] B. Sepehri and R. Ghavami, "Design of new CD38 inhibitors based on CoMFA modelling and molecular docking analysis of 4-amino-8-quinoline carboxamides and 2,4-diamino-8-quinazoline carboxamides," *SAR QSAR Environ. Res.*, vol. 30, no. 1, pp. 21–38, Jan. 2019, doi: 10.1080/1062936X.2018.1545695.
- [36] S. C. Peter, J. K. Dhanjal, V. Malik, N. Radhakrishnan, M. Jayakanthan, and D. Sundar, "Quantitative Structure-Activity Relationship (QSAR): Modeling Approaches to Biological Applications," in *Encyclopedia of Bioinformatics and Computational Biology*, Elsevier, 2019, pp. 661–676.
- [37] J. F. Aranda, D. E. Baceo, M. S. Leguizamón Aparicio, M. A. Ocsachoque, E. A. Castro, and P. R. Duchowicz, "Predicting the bioconcentration factor through a conformation-independent QSPR study," *SAR QSAR Environ. Res.*, vol. 28, no. 9, pp. 749–763, Sep. 2017, doi: 10.1080/1062936X.2017.1377765.
- [38] P. Gramatica, "Principles of QSAR models validation: internal and external," *QSAR Comb. Sci.*, vol. 26, no. 5, pp. 694–701, May 2007, doi: 10.1002/qsar.200610151.
- [39] "Descriptor List — mordred 1.2.1a1 documentation." [Online]. Available: <https://mordred-descriptor.github.io/documentation/master/descriptors.html>. [Accessed: 24-Nov-2019].
- [40] "DEDUCT | Database of Endocrine Disrupting chemicals and their Toxicity profiles." [Online]. Available: <https://cb.imsc.res.in/deduct/descriptors/eJaFhpFsbWo>. [Accessed: 24-Nov-2019].
- [41] "Machine Learning Glossary | Google Developers." [Online]. Available: <https://developers.google.com/machine-learning/glossary>. [Accessed: 26-Nov-2019].
- [42] S. Park and N. Kwak, "Analysis on the Dropout Effect in Convolutional Neural Networks," in *Computer Vision – ACCV 2016*, vol. 10112, S.-H. Lai, V. Lepetit, K. Nishino, and Y. Sato, Eds. Cham: Springer International Publishing, 2017, pp. 189–204.
- [43] R. D. Snee, "Validation of Regression Models: Methods and Examples," *Technometrics*, vol. 19, no. 4, pp. 415–428, Nov. 1977, doi: 10.1080/00401706.1977.10489581.